Xtant Medical Holdings, Inc. (XTNT)
NYSEAMERICAN: XTNT · Real-Time Price · USD
0.6950
-0.0123 (-1.74%)
Jun 6, 2025, 4:00 PM - Market closed
Xtant Medical Holdings Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xtant Medical Holdings.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Xtant Medical Holdings.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $2 → $3 | Strong Buy | Maintains | $2 → $3 | +331.65% | May 16, 2024 |
| BTIG | BTIG | Strong Buy Initiates $2 | Strong Buy | Initiates | $2 | +187.77% | Dec 5, 2023 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $1 → $1.2 | Strong Buy | Maintains | $1 → $1.2 | +72.66% | Jul 11, 2023 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $1 | Strong Buy | Initiates | $1 | +43.88% | Apr 26, 2023 |
Financial Forecast
Revenue This Year
130.92M
from 117.27M
Increased by 11.64%
Revenue Next Year
140.86M
from 130.92M
Increased by 7.59%
EPS This Year
-0.04
from -0.12
EPS Next Year
-0.02
from -0.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 136.8M | 146.9M |
| Avg | 130.9M | 140.9M |
| Low | 123.9M | 133.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 16.7% | 12.2% |
| Avg | 11.6% | 7.6% |
| Low | 5.6% | 2.0% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -0.02 | - |
| Avg | -0.04 | -0.02 |
| Low | -0.05 | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.